- Report
- August 2025
- 178 Pages
Global
From €3159EUR$3,599USD£2,748GBP
- Report
- April 2025
- 122 Pages
Europe
From €3028EUR$3,450USD£2,635GBP
- Report
- April 2025
- 129 Pages
Asia Pacific
From €3028EUR$3,450USD£2,635GBP
- Report
- April 2025
- 110 Pages
North America
From €3028EUR$3,450USD£2,635GBP
- Report
- April 2025
- 114 Pages
Africa, Middle East
From €3028EUR$3,450USD£2,635GBP
- Report
- July 2019
- 165 Pages
Global
From €4345EUR$4,950USD£3,780GBP
- Report
- April 2025
- 110 Pages
From €3028EUR$3,450USD£2,635GBP
- Report
- August 2024
- 182 Pages
Global
From €3906EUR$4,450USD£3,398GBP
- Report
- June 2024
- 185 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2024
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
Nicarbazin is an animal pharmaceutical used to treat coccidiosis, a parasitic disease that affects the digestive system of poultry. It is a combination of nicotinic acid and dinitrocarbanilide, and is used as a feed additive to prevent and control the spread of the disease. Nicarbazin is effective in controlling the spread of coccidiosis, and is used in poultry farms around the world. It is also used in other animals, such as pigs, horses, and sheep.
Nicarbazin is available in a variety of forms, including powder, granules, and tablets. It is also available in a variety of concentrations, depending on the species of animal being treated. The cost of Nicarbazin varies depending on the form and concentration, but is generally affordable.
The Nicarbazin market is highly competitive, with many companies offering their own versions of the product. Some of the major players in the market include Elanco, Merck Animal Health, Zoetis, Bayer Animal Health, and Novartis Animal Health. Show Less Read more